Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aptose Biosciences Inc APTO


Primary Symbol: T.APS

Healthcare Biotechnology
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti... see more

Recent & Breaking News (TSX:APS)

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

GlobeNewswire 17 hours ago

Aptose Reports Results for the Fourth Quarter and Full Year 2023

GlobeNewswire March 26, 2024

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

GlobeNewswire March 18, 2024

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

GlobeNewswire January 31, 2024

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

GlobeNewswire January 26, 2024

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

GlobeNewswire December 9, 2023

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

GlobeNewswire November 30, 2023

Aptose Reports Results for the Third Quarter 2023

GlobeNewswire November 9, 2023

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

GlobeNewswire November 2, 2023

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

GlobeNewswire October 30, 2023

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023

GlobeNewswire October 26, 2023

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

GlobeNewswire October 23, 2023

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

GlobeNewswire October 16, 2023

Aptose to Present at the Cantor Global Healthcare Conference

GlobeNewswire September 18, 2023

Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

GlobeNewswire September 6, 2023

Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire August 24, 2023

Aptose Reports Results for the Second Quarter 2023

GlobeNewswire August 10, 2023

Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023

GlobeNewswire July 27, 2023

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

GlobeNewswire June 26, 2023

Aptose Presents Highlights from Clinical Update

GlobeNewswire June 10, 2023